Uroguanylin (Dolcanatide)
Overview
Uroguanylin is a 16-amino acid endogenous peptide structurally related to guanylin that also activates guanylate cyclase-C receptors in the intestinal epithelium. It regulates fluid and electrolyte secretion in the gut and plays a role in satiety signaling and metabolic homeostasis. The synthetic analog dolcanatide has been developed to mimic uroguanylin's effects with enhanced stability and bioavailability. Like guanylin, uroguanylin increases cyclic GMP levels, promoting intestinal secretion and motility.
Key Research Findings
Dolcanatide has been evaluated in clinical trials for chronic constipation and constipation-predominant irritable bowel syndrome, demonstrating improved bowel function in early-phase studies. A phase 2 trial published in 2011 showed dose-dependent increases in bowel movement frequency and stool consistency. Further clinical development has been limited, and the agent has not achieved regulatory approval.
Oral
In Clinical Trials
Interested in Uroguanylin (Dolcanatide)?
Find a verified provider experienced with Uroguanylin (Dolcanatide) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Uroguanylin (Dolcanatide) ProviderRelated Peptides
Octreotide (Sandostatin)
FDA ApprovedA synthetic octapeptide analog of somatostatin with a substantially longer half-life (90 minutes IV, 6 hours subcutaneous vs. 2 minutes for native somatostatin). Octreotide binds somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit the secretion of GH, glucagon, insulin, gastrin, secretin, VIP, and other GI hormones. It reduces splanchnic blood flow, GI motility, and exocrine pancreatic secretion.
Lanreotide (Somatuline Depot)
FDA ApprovedA synthetic octapeptide analog of somatostatin with high affinity for SSTR2 and moderate affinity for SSTR5 receptors. Lanreotide is formulated as a supersaturated solution that forms a drug depot at the injection site, providing sustained release over 4 weeks. It inhibits GH secretion, GI hormone release, and has direct antiproliferative effects on neuroendocrine tumor cells through cell cycle arrest and apoptosis induction.
Pasireotide (Signifor)
FDA ApprovedA multireceptor-targeted somatostatin analog with high binding affinity for SSTR1, SSTR2, SSTR3, and SSTR5, particularly notable for its 40-fold greater affinity for SSTR5 compared to octreotide. This receptor profile makes pasireotide uniquely effective in Cushing's disease, where corticotroph adenomas predominantly express SSTR5. Pasireotide suppresses ACTH secretion from pituitary corticotroph tumors, reducing cortisol production.
Plecanatide (Trulance)
FDA ApprovedA synthetic 16-amino acid peptide structurally related to uroguanylin, an endogenous intestinal peptide that regulates fluid and electrolyte homeostasis in the GI tract. Plecanatide activates guanylate cyclase-C (GC-C) receptors on intestinal epithelial cells in a pH-dependent manner, preferentially in the proximal small intestine where pH is slightly acidic. GC-C activation increases intracellular and extracellular cGMP, stimulating chloride and bicarbonate secretion while reducing visceral pain signaling.